B
oston-based Cambridgeport Labs has secured its first tenant, French biotech company TreeFrog Therapeutics. The 13,488 square foot lease marks a significant milestone for the lab space, which was acquired by Greatland Realty Partners and Barings in 2022.

    TreeFrog Therapeutics specializes in cell therapy and aims to improve access to life-saving treatments for millions of patients worldwide. According to Kevin Alessandri, Co-founder and President & Executive Director of TreeFrog US, the new location will enable the company to expand its operations and deepen interactions with partners within the Boston ecosystem.

    The lease represents a major step in TreeFrog's global strategy, transitioning from an incubator space in Kendall Square to a dedicated lab and office. East Cambridge is a hub for life sciences, and Greatland Realty Partners' Teri Ford expressed pride in welcoming TreeFrog Therapeutics as their first tenant.

    "We're pleased to provide high-quality workspaces that attract innovative companies like TreeFrog," said Christopher Cassella, Managing Director at Barings. Newmark represented Greatland and Barings, while Colliers represented TreeFrog Therapeutics in the transaction.